BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Vardenafil Treatment Of Erectile Dysfunction In Depressive And Non-Depressive Men
- First Posted Date
- 2007-05-08
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2471
- Registration Number
- NCT00470873
Assessment of Compliance With Antihypertensive Telmisartan Therapy
- First Posted Date
- 2007-05-08
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3400
- Registration Number
- NCT00470886
The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension
- First Posted Date
- 2007-05-08
- Last Posted Date
- 2010-01-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 5448
- Registration Number
- NCT00471003
A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children
Phase 1
Completed
- Conditions
- Magnetic Resonance Imaging
- Interventions
- First Posted Date
- 2007-05-03
- Last Posted Date
- 2015-07-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 140
- Registration Number
- NCT00468819
Efficacy and Safety Study for an Oral Contraceptive Containing Folate
Phase 3
Completed
- Conditions
- Neural Tube DefectsContraceptionOral Contraceptives (OC)
- Interventions
- Drug: Drospirenone/Ethinylestradiol/MethyltetrahydrofolateDrug: Drospirenone/Ethinylestradiol (Yaz)
- First Posted Date
- 2007-05-02
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 385
- Registration Number
- NCT00468481
- Locations
- 🇺🇸
NorthWest Kinetics, Tacoma, Washington, United States
🇺🇸Lyndhurst Gynecologic Associates, Winston-Salem, North Carolina, United States
🇺🇸Orange County Clinical Trials, Anaheim, California, United States
Efficacy of Gynodian® Depot in Women With Impaired Well-being
Phase 3
Completed
- Conditions
- Hormone Replacement Therapy
- Interventions
- Drug: Gynodian® Depot (BAY86-5032)Drug: BAY86-4980
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 140
- Registration Number
- NCT00463450
Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea
Phase 2
Completed
- Conditions
- Dysmenorrhea
- Interventions
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 420
- Registration Number
- NCT00461305
Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
Completed
- Conditions
- Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: Interferon-1beta (Betaseron, BAY86-5046)
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 104
- Registration Number
- NCT00461396
FDA Phase IV - Commitment - Retinal Function Study
Phase 4
Completed
- Conditions
- Safety
- Interventions
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2015-03-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 63
- Registration Number
- NCT00461565
Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy
Phase 2
Completed
- Conditions
- Prostatic Hypertrophy, Benign
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 50
- Registration Number
- NCT00461123
© Copyright 2025. All Rights Reserved by MedPath